肺动脉血栓栓塞与组织型纤溶酶原激活剂及纤溶酶原激活物抑制剂的关系  

Study on the relationship of pulmonary thromboembolism with tissue plasminogen activator and its inhibitor

作　　者：马涵英[1] 赵铁夫[1] 雒芳芳[1] 张维君[1] 温绍君[1] 

机构地区：[1]首都医科大学附属北京安贞医院十二病房,100029

出　　处：《中华老年心脑血管病杂志》2010年第11期967-969,共3页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

基　　金：首都医学发展科研基金(zd199912)

摘　　要：目的探讨组织型纤溶酶原激活剂及纤溶酶原激活物抑制剂1血浆水平、基因多态性与肺动脉血栓栓塞(肺栓塞)的关系。方法选择肺栓塞患者87例(肺栓塞组),另选健康体检者80例(对照组),采用酶联免疫吸附法检测2组组织型纤溶酶原激活剂及纤溶酶原激活物抑制剂1血浆水平。聚合酶链反应-限制性片段长度多态性技术检测纤溶酶原激活物抑制剂1基因多态性。结果肺栓塞组患者较对照组血浆组织型纤溶酶原激活剂明显下降、纤溶酶原激活物抑制剂1明显升高。肺栓塞组4G/4G基因型频率明显高于对照组(51.7% vs 25.0%,P<0.05)。肺栓塞组和对照组均以4G/4G基因型个体的纤溶酶原激活物抑制剂1血浆水平最高,5G/5G基因型最低,4G/5G基因型居中。结论肺栓塞患者存在纤溶异常,4G/4G基因型患者呈明显低纤溶状态。Objective To study the relationship of plasminogen activator and plasminogen activator inhibitor-1（PAI-1） with pulmonary thromboembolism（PTE）. To investigate the change of tissue plasminogen activator（t-PA） and PAI-1 in the occurrence and development of PTE. Methods Eighty-seven patients with PTE（PTE group） and 80 sex and age matched healthy people（control group） were recruited in this study. Plasma tPA and PAI-1 were measured with ELISA. The subjects were genotyped for the 4G/5G polymorphism of PAI-1 gene using polymerase chain reaction based restriction fragment length polymorphism analysis. Results Plasma t-PA decreased significantly while plasma PAI-1 significantly elevated in PTE group compared with those of control group. The frequencies of genotype 4G/4G in PTE group was significantly higher than that in control group（51.7% vs 25.0%, P 〈 0.05）. Plasma PAI-1 level in 4G homozygous genotype was significantly higher than that in 4G/5G heterozygous and 5G homozygous genotypes in both groups. Conclusion There were hypofibrinolysis and hypercoagulation in PTE patients especially who were in 4G homozygous genotype.

关 键 词：肺栓塞 纤溶酶原激活剂 纤溶酶原灭活剂 多态现象 遗传 基因型 启动区(遗传学) 4G/5G多态性 

分 类 号：R563.5[医药卫生—呼吸系统]